Lonza launches AI-enabled route scouting
Lonza has launched its AI-enabled route scouting service offering for small molecules, which combines AI-enabled computer-aided synthesis planning technology from Elsevier operation Reaxys with its own process R&D expertise and supply chain databases. This aims to streamline synthetic route identification.
“The complexity of small molecule APIs entering the development pipeline is steadily increasing, and the intricate structures of modern drug candidates are driving an increase in the number of synthetic steps required to produce them,” the company noted. This adds up to more raw materials and longer lead times, often increasing the time and cost of developing an effective synthesis.
RELATED ARTICLES
Swiss CDMO Siegfried has inaugurated its new global R&D centre for drug substances at its site in Evionnaz.
Peptides CDMO AmbioPharm, has broken ground on a 650 m2, $28 million expansion project at its Shanghai manufacturing site. This is due to be complete in 2H 2025 and will produce over 8 tonnes/year of crude peptide.
Three CDMOs have separately announced expansions in their antibody-drug conjugate (ADC) manufacturing capabilities and capacity on opposite sides of the Atlantic.
Biosynth, which supplies critical raw materials and services for diagnostics, vaccines and pharmaceuticals, has officially opened its Biosynth Biological Technology site at Lifebay, a technology park in Suzhou, China.
At its latest Capital Markets Day, Merck KGaA said that it is “in a strong strategic position” to profit from medium-term growth opportunities in all three of its business sectors after a transitional year in 2023.
At CPHI in Milan in October, eight Indian CDMOs announced that they have formed a trade group to raise the profile of India’s drug services sector and make it a destination of choice.
